Proton beam radiotherapy for choroidal and ciliary body melanoma in the UK-national audit of referral patterns of 1084 cases.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
25
03
2022
accepted:
07
07
2022
revised:
03
07
2022
pmc-release:
01
04
2024
medline:
30
3
2023
pubmed:
16
7
2022
entrez:
15
7
2022
Statut:
ppublish
Résumé
Proton beam therapy has been utilised for the treatment of uveal melanoma in the UK for over 30 years, undertaken under a single centre. In the UK, all ocular tumours are treated at one of four centres. We aimed to understand the variation in referral patterns to the UK proton service, capturing all uveal melanoma patients treated with this modality. Retrospective analysis of data regarding all patients treated at the Clatterbridge Proton service between January 2004 and December 2014. A total of 1084 patients with uveal melanoma were treated. The mean age was 57 years (range 9-90 years), basal diameter of 11.5 mm (range 2.0-23.4 mm) and tumour thickness of 3.9 mm (range 0.1-15.4 mm). The majority were TNM stage I (39%) or II (36%). The distance to the optic nerve varied from 0 to 24.5 mm with 148 (14%) of patients having ciliary body involvement. There were variations in the phenotypic characteristic of the tumours treated with protons from different centres, with London referring predominantly small tumours at the posterior pole, Glasgow referring large tumours often at the ciliary body and Liverpool sending a mix of these groups. In the UK, common indications for the use of proton treatment in uveal melanoma include small tumours in the posterior pole poorly accessible for plaque treatment (adjacent to the disc), tumours at the posterior pole affecting the fovea and large anterior tumours traditionally too large for brachytherapy. This is the first UK-wide audit enabling the capture of all patients treated at the single proton centre.
Identifiants
pubmed: 35840716
doi: 10.1038/s41433-022-02178-0
pii: 10.1038/s41433-022-02178-0
pmc: PMC10050435
doi:
Substances chimiques
Protons
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1033-1036Informations de copyright
© 2022. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
Durante M, Orecchia R, Loeffler JS. Charged-particle therapy in cancer: clinical uses and future perspectives. Nat Rev Clin Oncol. 2017;14:483–95.
doi: 10.1038/nrclinonc.2017.30
pubmed: 28290489
Goossens ME, Van den Bulcke M, Gevaert T, Meheus L, Verellen D, Cosset JM, et al. Is there any benefit to particles over photon radiotherapy? Ecancermedicalscience. 2019;13:982.
doi: 10.3332/ecancer.2019.982
pubmed: 32010206
pmcid: 6974365
Schreuder AN, Shamblin J. Proton therapy delivery: what is needed in the next ten years? Br J Radio. 2020;93:20190359.
doi: 10.1259/bjr.20190359
Burnet NG, Mackay RI, Smith E, Chadwick AL, Whitfield GA, Thomson DJ, et al. Proton beam therapy: perspectives on the National Health Service England clinical service and research programme. Br J Radio. 2020;93:20190873.
doi: 10.1259/bjr.20190873
Gragoudas ES, Goitein M, Koehler AM, Verhey L, Tepper J, Suit HD, et al. Proton irradiation of small choroidal malignant melanomas. Am J Ophthalmol. 1977;83:665–73.
doi: 10.1016/0002-9394(77)90133-7
pubmed: 405869
Hrbacek J, Mishra KK, Kacperek A, Dendale R, Nauraye C, Auger M, et al. Practice patterns analysis of ocular proton therapy centers: the International OPTIC Survey. Int J Radiat Oncol Biol Phys. 2016;95:336–43.
doi: 10.1016/j.ijrobp.2016.01.040
pubmed: 27084651
Verma V, Mehta MP. Clinical outcomes of proton radiotherapy for uveal melanoma. Clin Oncol (R Coll Radio). 2016;28:e17–27.
doi: 10.1016/j.clon.2016.01.034
Wang Z, Nabhan M, Schild SE, Stafford SL, Petersen IA, Foote RL, et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86:18–26.
doi: 10.1016/j.ijrobp.2012.08.026
pubmed: 23040219
Boldt HC, Binkley E. Treating small choroidal melanoma: smaller is better. JAMA Ophthalmol. 2018;136:1333–4.
doi: 10.1001/jamaophthalmol.2018.3880
pubmed: 30267041
Hussain R, Czanner G, Taktak A, Damato B, Praidou A, Heimann H. Mortality of patients with uveal melanoma detected by diabetic retinopathy screening. Retina. 2020;40:2198–2206.
Jouhi S, Jager MJ, de Geus SJR, Desjardins L, Eide NA, Grange JD, et al. The Small Fatal Choroidal Melanoma Study. A survey by the European Ophthalmic Oncology Group. Am J Ophthalmol. 2019;202:100–8.
doi: 10.1016/j.ajo.2019.01.031
pubmed: 30772347
Toutee A, Angi M, Dureau S, Levy-Gabriel C, Rouic LL, Dendale R, et al. Long-term visual outcomes for small uveal melanoma staged T1 treated by proton beam radiotherapy. Cancers (Basel). 2019;11:1047.
Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys. 2005;63:385–91.
doi: 10.1016/j.ijrobp.2005.02.017
pubmed: 15913907
Kacperek A. Protontherapy of eye tumours in the UK: a review of treatment at Clatterbridge. Appl Radiat Isot. 2009;67:378–86.
doi: 10.1016/j.apradiso.2008.06.012
pubmed: 18675550
Sikuade MJ, Salvi S, Rundle PA, Errington DG, Kacperek A, Rennie IG. Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma. Eye (Lond). 2015;29:1194–8.
doi: 10.1038/eye.2015.109
pubmed: 26160531
Mishra KK, Daftari IK. Proton therapy for the management of uveal melanoma and other ocular tumors. Chin Clin Oncol. 2016;5:50.
doi: 10.21037/cco.2016.07.06
pubmed: 27558251
Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, Cassoux N, Dendale R, Mazal A, et al. Treatment of uveal melanoma by accelerated proton beam. Dev Ophthalmol. 2012;49:41–57.
doi: 10.1159/000328257
pubmed: 22042012
Kamran SC, Collier JM, Lane AM, Kim I, Niemierko A, Chen YL, et al. Outcomes of proton therapy for the treatment of uveal metastases. Int J Radiat Oncol Biol Phys. 2014;90:1044–50.
doi: 10.1016/j.ijrobp.2014.08.003
pubmed: 25442038
Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys. 2005;62:1405–11.
doi: 10.1016/j.ijrobp.2005.01.016
pubmed: 16029800
Egger E, Zografos L, Schalenbourg A, Beati D, Bohringer T, Chamot L, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2003;55:867–80.
doi: 10.1016/S0360-3016(02)04200-1
pubmed: 12605964
Egger E, Zografos L, Munkel G, Bohringer T, Bercher L, Chamot L. Results of proton radiotherapy for uveal melanomas. Front Radiat Ther Oncol. 1997;30:111–22.
doi: 10.1159/000425694
pubmed: 9205891
Gragoudas ES. 1996 Jules Gonin Lecture of the Retina Research Foundation. Long-term results after proton irradiation of uveal melanomas. Graefes Arch Clin Exp Ophthalmol. 1997;235:265–7.
doi: 10.1007/BF01739634
pubmed: 9176673
Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, Dendale R, Delacroix S, Nauraye C, et al. Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. Ophthalmic Res. 2006;38:255–60.
doi: 10.1159/000094834
pubmed: 16888407
Pica A, Weber DC, Vallat L, Bergin C, Hrbacek J, Schweizer C, et al. Good long-term visual outcomes of parapapillary choroidal melanoma patients treated with proton therapy: a comparative study. Int Ophthalmol. 2021;41:441–52.
doi: 10.1007/s10792-020-01594-z
pubmed: 32975693
Thariat J, Grange JD, Mosci C, Rosier L, Maschi C, Lanza F, et al. Visual outcomes of parapapillary uveal melanomas following proton beam therapy. Int J Radiat Oncol Biol Phys. 2016;95:328–35.
doi: 10.1016/j.ijrobp.2015.12.011
pubmed: 27084650
Hussain R, Heussen FM, Heimann H. OCT changes in peri-tumour normal retina following ruthenium-106 and proton beam radiotherapy for uveal melanoma. Br J Ophthalmol. 2021;105:648–52.